Association of Body Composition and Other Clinical Factors with Incomplete Immune Response after Highly Active Antiretroviral Therapy

Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2017 Aug 20;39(4):459-464. doi: 10.3881/j.issn.1000-503X.2017.04.001.

Abstract

Objective To explore whether baseline body composition and other clinical factors are associated with incomplete immune response after highly active antiretroviral therapy(HAART)in Chinese men with human immunodeficiency virus(HIV)or acquired immunodeficiency syndrome(AIDS).Methods A retrospective study was conducted among HIV/AIDS male patients who achieved viral suppression(maintained HIV-1 RNA levels<400 copies/ml)after a year of HAART between 2007 and 2015.Clinical,immunological,and virological data were collected from patients' files,including weight,height,and whole body composition measured within one month prior to staring HAART.Body mass index(BMI),lean mass index(LMI),fat mass index(FMI),and body bone mineral content/height were adjusted by height.According to whether the patients experienced incomplete immune responses(CD4 cell count<350 cells/μl)after a year of HAART,the patients were divided into two groups:the complete immune response(CD4 cell count≥350 cells/μl)and the incomplete immune response(CD4 cell count<350 cells/μl),respectively.Student's t test,chi-square test,and Wilcoxon rank test were used to assess differences between these two groups.Multiple Logistic regression analysis was used to assess factors associated with an incomplete immune response in patients with sustained viral suppression.Results Totally 84 HIV/AIDS male patients with viral suppression were included in this study.There were statistical differences between these two groups in terms of age(Z=-2.479,P=0.013),baseline BMI(t=2.030,P=0.045),LMI(t=2.200,P=0.029),and CD4 cell count(Z=6.416,P=0.000).However,there was no statistical differences in viral load,FMI,body bone mineral content/height,HAART duration,and HAART regimen(all P>0.05).BMI[OR=0.742,95% confidence interval(CI)=0.554-0.993,P=0.044],LMI(OR=0.459,95% CI=0.249-0.844,P=0.012),HAART duration(OR=10.161,95% CI=1.110-93.052,P=0.040),baseline CD4 cell count(OR=80.051,95% CI=8.396-762.563,P=0.000)were significantly associated with incomplete immune response.Age(OR=1.497,95% CI=0.213-10.505,P=0.685),viral load(OR=0.333,95% CI=0.071-1.572,P=0.164),FMI(OR=0.797,95% CI=0.546-1.164,P=0.240),body bone mineral content/height(OR=1.145,95% CI=0.037-35.676,P=0.938)and HAART regimen(OR=0.430,95% CI=0.159-1.159,P=0.095)were not associated with incomplete immune response.Conclusions Baseline CD4 cell count and HAART duration may affect immune response.Patients with higher baseline BMI or higher LMI may be less likely to develop incomplete immune response.Baseline FMI and body bone mineral content/height ratio are not associated with incomplete immune response.

目的 分析不同体成分及其他因素与中国男性人类免疫缺陷病毒(HIV)或获得性免疫缺陷综合征(AIDS)患者接受高效抗逆转录病毒治疗(HAART)后免疫重建不全的相关性。方法 回顾性分析2007年至2015年接受HAART 1年以上并获得病毒抑制(HIV-1 RNA<400拷贝/ml)的男性HIV/AIDS患者资料,包括患者临床、免疫学及病毒学资料,其中包括HAART开始前1个月内测量的患者体质量、身高、全身体成分。经身高校正后得到体质量指数(BMI)、肌肉指数(LMI)、脂肪指数(FMI)、骨矿含量/身高。根据患者接受HAART 1年后是否出现免疫重建不全(CD4细胞计数<350细胞/μl),将患者分为免疫学未完全应答组(CD4细胞计数<350细胞/μl)、免疫学完全应答组(CD4细胞计数≥350细胞/μl)。应用t检验、卡方检验及Wilcoxon秩和检验比较两组患者的差异,应用多因素Logistics回归分析接受HAART 1年后免疫重建不全的影响因素。结果 共纳入84例男性HIV/AIDS患者。两组患者的年龄(Z=-2.479,P=0.013)、基线BMI(t=2.030,P=0.045)、LMI(t=2.200,P=0.029)、CD4细胞计数(Z=6.416,P=0.000)差异有统计学意义。两组患者的基线病毒载量、FMI、骨矿含量/身高、HAART时间、HAART方案差异无统计学意义(P>0.05)。BMI(OR=0.742,95% CI=0.554-0.993,P=0.044)、LMI(OR=0.459,95% CI=0.249-0.844,P=0.012)、 HAART时间(OR=10.161,95% CI=1.110-93.052,P=0.040)、基线 CD4 细胞计数(OR=80.051,95% CI=8.396-762.563,P=0.000)与免疫重建不全具有相关性。年龄(OR=1.497,95% CI=0.213-10.505,P=0.685)、病毒载量(OR=0.333,95% CI=0.071-1.572,P=0.164)、FMI(OR=0.797,95% CI=0.546-1.164,P=0.240)、全身骨矿含量/身高(OR=1.145,95% CI=0.037-35.676,P=0.938)及HAART方案(OR=0.430,95% CI=0.159-1.159,P=0.095)与免疫重建不全无相关性。结论 基线CD4细胞计数及治疗时间可影响免疫重建,基线BMI或基线LMI较高是免疫重建不全的保护因素,基线FMI和全身骨矿物质含量/身高与免疫重建不全无关。.

MeSH terms

  • Antiretroviral Therapy, Highly Active*
  • Body Composition*
  • CD4 Lymphocyte Count
  • HIV Infections / drug therapy*
  • HIV Infections / immunology
  • Humans
  • Male
  • Retrospective Studies
  • Viral Load